KEI Intervention at WIPO’s SCP 20 on Patents and Health
SCP20: Opening statement of the European Union at WIPO’s Standing Committee on the Law of Patents, 27 January 2014
On 27 January 2014, Greece, on behalf of the European Union, delivered this opening statement at the 20th session of WIPO Standing Committee on the Law of Patents (SCP). The EU’s priorities for WIPO’s patent committee include quality of patents (including opposition systems), work sharing and confidentiality of communication between client and their patent advisors.
With respect to limitations and exceptions to patent rights, the EU said,
Industry use of WHO Model List of Essential Medicines as defense against patent abuses
The following are some quotes by countries, companies, academics and other actors stating, suggesting or implying claiming that drugs not on the WHO Model List of Essential Medicines (WHO EML) should not be subject to a compulsory license.
Bayer. Political Principles.
http://www.bayer.com/en/innovation-requires-investment.aspx
Political Principles.
Innovation requires investment.
Good ideas must be worthwhile.Blogs and Press coverage of Pharma/Medicine device industry lobbying on South Africa patent reform (pharmagate)
Boseley, Sarah. 17 January 2014. “South African pharma firms accused of planning to delay patents law reform.” The Guardian. http://www.theguardian.com/world/2014/jan/17/south-african-pharma-accused-delay-patents-law-reform
De Wet, Phillip. 17 January 2014. “Motsoaledi: Big pharma’s ‘satanic’ plot is genocide.” Mail & Guardian. http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
New leaked Merck missive reveals deep drug, medical device company opposition to South African patent reforms
James K. Glassman. Merck said Glassman’s public relations firm was selected by PhRMA to lead a campaign to keep drug prices high in South Africa. The Health Minister in South Africa referred to the campaign proposal as a genocidal conspiracy of satanic magnitude. 2007 Report and Decision of WIPO General Assembly on Diplomatic Conference for Broadcasting Organizations
WO/GA/34/16
ITEM 17 OF THE CONSOLIDATED AGENDA:
REPORT ON THE SPECIAL SESSIONS OF THE STANDING COMMITTEE ON COPYRIGHT AND RELATED RIGHTS REGARDING THE PROPOSED DIPLOMATIC CONFERENCE ON THE PROTECTION OF THE RIGHTS OF BROADCASTING ORGANIZATIONS
202 Discussions were based on document WO/GA/34/8.
203 Referring to document WO/GA/34/8, the Secretariat summarized the previous discussions and the recommendation from the Second Special Session of the Standing Committee on Copyright and Related Rights (SCCR).
AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Amgen’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Item 1A. RISK FACTORS
Eli Lilly’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Eli Lilly’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in Item 1A: 2168
Compulsory licensing of patents: 0Item 1A. Risk Factors
Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012
From Gilead’s 10-K, section on Risk Factors, for fiscal year ended December 31, 2012.
Number of words in section 1A: 12709
Words on compulsory licenses: 396ITEM 1A. RISK FACTORS
